drugset
drugset / Trial / NCT00397293

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

NCT00397293 ↗

Phase 1/2 Completed 36 enrolled Ascenta Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with topotecan in relapsed/refractory small cell lung cancer

Timeline

Start
2006-11
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AT-101 Small molecule 40 mg Oral
Subject Topotecan Small molecule 1.25 mg/m2 Intravenous

Indications

small cell lung carcinoma